Shares of Orthofix International N.V. (NASDAQ:OFIX) have been assigned an average rating of “Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $53.30.

Several equities analysts have commented on the company. Jefferies Group reiterated a “buy” rating and issued a $55.00 target price (up from $50.00) on shares of Orthofix International in a research report on Thursday, August 10th. Zacks Investment Research downgraded Orthofix International from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. TheStreet downgraded Orthofix International from a “b” rating to a “c+” rating in a research report on Tuesday, October 31st. BTIG Research set a $56.00 target price on Orthofix International and gave the company a “buy” rating in a research report on Monday, October 30th. Finally, BidaskClub upgraded Orthofix International from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th.

In other news, Director Luke T. Faulstick sold 4,800 shares of the stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $51.22, for a total value of $245,856.00. Following the completion of the sale, the director now owns 7,729 shares of the company’s stock, valued at $395,879.38. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Brad Mason sold 5,000 shares of the stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total value of $267,400.00. Following the completion of the sale, the chief executive officer now directly owns 183,053 shares of the company’s stock, valued at approximately $9,789,674.44. The disclosure for this sale can be found here. In the last three months, insiders sold 24,109 shares of company stock valued at $1,220,840. Insiders own 5.60% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Pinebridge Investments L.P. grew its stake in Orthofix International by 2.3% during the second quarter. Pinebridge Investments L.P. now owns 2,378 shares of the medical device company’s stock worth $111,000 after purchasing an additional 53 shares during the period. Arizona State Retirement System grew its stake in Orthofix International by 1.1% during the second quarter. Arizona State Retirement System now owns 9,400 shares of the medical device company’s stock worth $437,000 after purchasing an additional 100 shares during the period. Victory Capital Management Inc. grew its stake in Orthofix International by 1.2% during the second quarter. Victory Capital Management Inc. now owns 32,089 shares of the medical device company’s stock worth $1,491,000 after purchasing an additional 365 shares during the period. AJO LP grew its stake in Orthofix International by 0.4% during the second quarter. AJO LP now owns 169,162 shares of the medical device company’s stock worth $7,863,000 after purchasing an additional 702 shares during the period. Finally, Voya Investment Management LLC grew its stake in Orthofix International by 10.7% during the second quarter. Voya Investment Management LLC now owns 8,622 shares of the medical device company’s stock worth $401,000 after purchasing an additional 832 shares during the period. 94.61% of the stock is owned by institutional investors.

Shares of Orthofix International (NASDAQ OFIX) opened at $53.10 on Friday. Orthofix International has a 1 year low of $32.51 and a 1 year high of $54.73. The firm has a market capitalization of $961.14, a price-to-earnings ratio of 34.46, a P/E/G ratio of 2.61 and a beta of 0.14.

Orthofix International (NASDAQ:OFIX) last posted its earnings results on Monday, October 30th. The medical device company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.41 by $0.01. The firm had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the company earned $0.36 earnings per share. equities analysts forecast that Orthofix International will post 1.61 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/08/orthofix-international-n-v-ofix-given-consensus-recommendation-of-buy-by-brokerages.html.

About Orthofix International

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Analyst Recommendations for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.